|By Marketwired .||
|February 26, 2014 05:30 PM EST||
SYDNEY, AUSTRALIA -- (Marketwired) -- 02/26/14 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company") will present a corporate overview and provide an update of its CVac development program at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York City on Monday, March 3rd at 1:35 p.m. (U.S. Eastern Standard Time).
At the time of the presentation, a live webcast of Prima's presentation will be available at the following link: www.visualwebcaster.com/event.asp?id=98054.
After the presentation, an archived version of the webcast will be available on Prima's website at www.primabiomed.com.au.
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
About the Wall Street Analyst Forum Institutional Investor Conference
Since 1989, The Wall Street Analyst Forum has sponsored over 80 analyst conferences for NYSE/NASDAQ/AMEX corporations in New York, Boston & London. Over 2,200 different public corporations have presented and analysts & portfolio managers from over 2000 different institutions have attended in person & via webcast.